Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$1.1b

Viridian Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Viridian Therapeutics has a total shareholder equity of $442.0M and total debt of $20.2M, which brings its debt-to-equity ratio to 4.6%. Its total assets and total liabilities are $490.4M and $48.4M respectively.

Key information

4.6%

Debt to equity ratio

US$20.21m

Debt

Interest coverage ration/a
CashUS$477.37m
EquityUS$442.02m
Total liabilitiesUS$48.40m
Total assetsUS$490.42m

Recent financial health updates

Recent updates

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

Viridian Therapeutics reports Q1 results

May 06

Financial Position Analysis

Short Term Liabilities: VRDN's short term assets ($486.5M) exceed its short term liabilities ($26.6M).

Long Term Liabilities: VRDN's short term assets ($486.5M) exceed its long term liabilities ($21.8M).


Debt to Equity History and Analysis

Debt Level: VRDN has more cash than its total debt.

Reducing Debt: VRDN's debt to equity ratio has reduced from 20.1% to 4.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VRDN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VRDN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 36.3% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.